Trial reportJournal of clinical hypertension (Greenwich, Conn.)2004
Use of an olmesartan medoxomil-based treatment algorithm for hypertension control.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Remote blood pressure monitoring and behavioral intensification for stroke: A randomized controlled feasibility trial.PloS one · 2020Trial
- Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study.Clinical drug investigation · 2010Trial
- The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older.Journal of clinical hypertension (Greenwich, Conn.) · 2009Trial
- Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study.Vascular health and risk management · 2009Trial
- Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study.Journal of clinical hypertension (Greenwich, Conn.) · 2007Trial
- Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.Clinical drug investigation · 2007Trial
- Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker.Journal of clinical hypertension (Greenwich, Conn.) · 2007Trial
- Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension.Journal of human hypertension · 2006Trial
- An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements.Journal of clinical hypertension (Greenwich, Conn.) · 2006Trial
- Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients.Journal of clinical hypertension (Greenwich, Conn.) · 2005Trial
- Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023Review
- Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017Review
- Rationale for triple-combination therapy for management of high blood pressure.Journal of clinical hypertension (Greenwich, Conn.) · 2010Review
- Role of olmesartan in combination therapy in blood pressure control and vascular function.Vascular health and risk management · 2010Review
- Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.Drugs · 2008Review
- Review
- Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.Vascular health and risk management · 2008Review
- Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension.Vascular health and risk management · 2006Review
- Roundtable discussion: blood pressure goal attainment: meeting the challenge of the JNC 7's blood pressure goals and the role of renin-angiotensin-aldosterone system blockade.Journal of clinical hypertension (Greenwich, Conn.) · 2004Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension guidelines recommend a stepped-care approach that starts with titration of the initial agent followed by the addition of other agents, as necessary, to achieve goal blood pressure. This study assessed the effectiveness of an antihypertensive treatment algorithm with olmesartan medoxomil as the initial agent. This was a 24-week, open-label trial in patients (N=201) with mean seated diastolic blood pressure of 90-109 mm Hg. Following placebo run-in, all patients received olmesartan medoxomil 20 mg/d for 4 weeks. At subsequent 4-week intervals, the regimen was modified in patients with blood pressure >130/85 mm Hg: up-titration of olmesartan medoxomil to 40 mg/d; addition of hydrochlorothiazide 12.5 mg/d; up-titration of hydrochlorothiazide to 25 mg/d; addition of amlodipine besylate 5 mg/d; and up-titration of amlodipine besylate to 10 mg/d. Patients who achieved blood pressure < or =130/85 mm Hg at any point exited the study with no further follow-up. At Week 24, reductions in blood pressure from baseline were 33.7/18.2 mm Hg. Altogether, 87.7% of patients reached the goal blood pressure of < or =130/85 mm Hg and 93.3% achieved a blood pressure of < or =140/90 mm Hg. Thus, an antihypertensive algorithm with olmesartan medoxomil as the initial agent controlled blood pressure in the majority of patients, but with >60% of patients also requiring the use of a thiazide diuretic or a thiazide and a calcium channel blocker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.